ImmunoACT has announced the appointment of V. Simpson Emmanuel as its new President, marking a significant leadership addition as the company strengthens its growth and global ambitions.
Emmanuel brings nearly three decades of experience in the pharmaceutical industry. Before joining ImmunoACT, he served as Managing Director and Chief Executive Officer of Roche Pharma India, where he played a key role in driving strong business growth and establishing market leadership across critical therapy areas.
He holds a master’s degree in Health Economics from the University of York and has deep expertise in Health Technology Assessment (HTA), equipping him with a strong understanding of market access, value-based healthcare, and strategic commercialization.
In his new role, Emmanuel will focus on strengthening market access, accelerating business growth, expanding ImmunoACT’s global footprint, and shaping the company’s commercial and marketing strategy. He will also play a pivotal role in advancing key initiatives, including ImmunoACT’s flagship #HOPEInitiative.